News
Merck KGaA/Pfizer's Bavencio fails in stomach cancer trial
Merck KGaA and Pfizer’s cancer immunotherapy Bavencio has disappointed in a hard to treat late-stage gastric cancer trial, failing to extend survival compared to chemotherapy.
